May 24, 2019 / 11:38 PM / a month ago

BRIEF-Regenxbio Announces First FDA Approval Of A Gene Therapy Based On Its Proprietary Nav Technology Platform

May 24 (Reuters) - Regenxbio Inc:

* REGENXBIO ANNOUNCES FIRST FDA APPROVAL OF A GENE THERAPY BASED ON ITS PROPRIETARY NAV® TECHNOLOGY PLATFORM

* REGENXBIO INC - ADDITIONAL APPROVALS FOR GENE THERAPY BASED ON ITS PROPRIETARY NAV® TECHNOLOGY PLATFORM ANTICIPATED IN EUROPE AND JAPAN IN 2019 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below